OKYO Pharma (OKYO) News Today $1.06 +0.01 (+0.47%) (As of 12/24/2024 01:48 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNovember 26, 2024 | markets.businessinsider.comOKYO Pharma to Highlight Innovations at BTIG ConferenceNovember 26, 2024 | tipranks.comJapan pharma mulls suing lawmaker who likened new COVID vaccine to 'biological weapon'November 2, 2024 | msn.comJapan's Takeda raises full-year profit forecast amid restructuringOctober 31, 2024 | msn.comOKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conferenceOctober 30, 2024 | proactiveinvestors.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMIOctober 26, 2024 | proactiveinvestors.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialOctober 23, 2024 | proactiveinvestors.comOKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOctober 23, 2024 | globenewswire.comOKYO Pharma Begins Key Phase 2 Trial for Eye Pain DrugOctober 18, 2024 | finance.yahoo.comOKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatmentOctober 16, 2024 | proactiveinvestors.comLife-saving cancer drug a boon for patients, but its price prompts debateSeptember 27, 2024 | msn.comBuy Rating on OKYO Pharma: U.S. Patent and Strong Trial Results for OK-101 Boosts Market PotentialAugust 27, 2024 | markets.businessinsider.comOKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseAugust 27, 2024 | markets.businessinsider.comOKYO Pharma secures key US patent for dry eye disease therapyAugust 27, 2024 | proactiveinvestors.comOKYO Pharma Exec Chairman Increases StakeAugust 25, 2024 | uk.investing.comOKYO Pharma CEO Interview to Air on Bloomberg TVAugust 23, 2024 | globenewswire.comOKYO Pharma Announces Chairman Acquires SharesAugust 23, 2024 | globenewswire.comOKYO Pharma chairman acquires more shares in the companyAugust 21, 2024 | proactiveinvestors.comOKYO Pharma Announces Chairman Acquires SharesAugust 21, 2024 | globenewswire.comOKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 15, 2024 | globenewswire.comOver 80% in Japan morning-after pill sales trial want to buy without prescription: reportAugust 14, 2024 | msn.comOKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseAugust 6, 2024 | globenewswire.comOKYO Pharma dry eye disease trial to get underway in the third quarterJuly 11, 2024 | proactiveinvestors.comOKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101July 11, 2024 | globenewswire.comOKYO Pharma shares encouraging dry eye dataJuly 10, 2024 | proactiveinvestors.comOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseJuly 10, 2024 | globenewswire.comExperts reveal plans to end 'drug loss,' where medicines approved overseas not used in JapanMay 17, 2024 | msn.comOKYO Pharma Announces Participation in May 2024 Investor ConferencesMay 8, 2024 | finance.yahoo.comOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)April 30, 2024 | globenewswire.comOKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventApril 9, 2024 | proactiveinvestors.comOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024April 8, 2024 | globenewswire.comOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryApril 2, 2024 | globenewswire.comJapan authorities inspect second Kobayashi Pharma factory after deathsMarch 31, 2024 | msn.comJapan dietary supplement maker probes five deathsMarch 29, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)March 27, 2024 | markets.businessinsider.comOKYO Pharma gains after positive results from Phase 2 dry eye disease trialMarch 22, 2024 | msn.comRelief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage StudyMarch 22, 2024 | msn.comOKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsMarch 22, 2024 | proactiveinvestors.comOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101March 22, 2024 | globenewswire.comOKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseMarch 21, 2024 | proactiveinvestors.comOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialMarch 21, 2024 | globenewswire.comOKYO Pharma to release Phase 2 dry eye disease trial results on FridayMarch 20, 2024 | proactiveinvestors.comOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventMarch 20, 2024 | globenewswire.comOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo FinanceMarch 19, 2024 | finance.yahoo.comTokyo stocks open lower as gains locked in, BOJ outcome awaitedMarch 19, 2024 | msn.comOKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12February 25, 2024 | msn.comTokyo stocks open flat as gains locked in, exporters riseFebruary 20, 2024 | msn.comOKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialFebruary 9, 2024 | proactiveinvestors.comOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainFebruary 9, 2024 | finance.yahoo.comStock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocksFebruary 2, 2024 | msn.com Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years. I call it my AI Retirement Playbook. I recommend you check it out now. OKYO Media Mentions By Week OKYO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼0.000.59▲Average Medical News Sentiment OKYO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼01▲OKYO Articles Average Week Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ATOS News IFRX News ENTA News CABA News VXRT News PLX News APLT News SAVA News IVA News EDIT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts